CROSSTEC (03893) releases interim results, shareholders' net loss of HK$13.052 million, turning from profit to loss on a year-on-year basis.
Yi Wei Group (03893) releases its interim financial results for the six months ending on December 31, 2024. The Group has achieved...
CROSSTEC (03893) announced its interim results for the six months ended December 31, 2024. The group achieved a revenue of HK$45.713 million, representing a year-on-year increase of 69.41%. The company's attributable loss was HK$13.052 million, compared to a profit of HK$6.722 million in the same period last year. The loss per share was 8.39 HK cents.
The group's comprehensive profit for the six months ended December 31, 2023 turned into a comprehensive loss for the current period mainly due to the following one-off items in the previous period: a reversal of contract costs of approximately HK$6.3 million, a reversal of expected losses on loss-making contracts of approximately HK$6.4 million, and a gain on early termination of leases of approximately HK$4.8 million. These items are non-cash and non-recurring in nature, and did not occur in the current period.
Related Articles

Nanjing Toua Hardware & Tools (301125.SZ) plans to raise no more than 120 million yuan through a simple program of additional shares issuance.

Zhejiang Huaye Plastics Machinery (301616.SZ) plans to implement the Mu'ao production base project (Phase II) to expand production capacity.

Dizhe Pharmaceuticals (688192.SH): Positive top-line results from international multicenter phase III clinical trial of Shuwozhe monotherapy for EGFRexon20ins non-small cell lung cancer.
Nanjing Toua Hardware & Tools (301125.SZ) plans to raise no more than 120 million yuan through a simple program of additional shares issuance.

Zhejiang Huaye Plastics Machinery (301616.SZ) plans to implement the Mu'ao production base project (Phase II) to expand production capacity.

Dizhe Pharmaceuticals (688192.SH): Positive top-line results from international multicenter phase III clinical trial of Shuwozhe monotherapy for EGFRexon20ins non-small cell lung cancer.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


